DOT and non-DOT drug tests may look similar at a collection site, but they are governed by different rules. A DOT test is performed under 49 CFR Part 40 and the regulation of the DOT agency responsible for the employee’s safety-sensitive work. For interstate commercial drivers subject to FMCSA testing, that agency rule is 49 CFR Part 382. A non-DOT test is controlled by the employer’s policy and applicable state or local law.
The safest operational rule is simple: never treat the two programs as interchangeable. The test reason, form, specimen process, laboratory, review, records and consequences must follow the program that applies to the employee and event.
DOT vs non-DOT drug testing at a glance
| Issue | DOT testing | Non-DOT testing |
|---|---|---|
| Rule source | 49 CFR Part 40 plus the applicable DOT agency regulation, including Part 382 for FMCSA-regulated drivers | Employer policy subject to applicable federal, state and local law |
| Who is covered | Employees performing safety-sensitive functions defined by a DOT agency rule | Employees selected under the employer’s lawful workplace policy |
| Drug panel | The five drug classes required by Part 40 | Chosen under the employer’s policy and governing law |
| Forms and process | Federal custody and control procedures and qualified Part 40 service agents | Non-federal forms and procedures chosen for the program |
| Positive or refusal outcome | Immediate removal from DOT safety-sensitive functions and the Part 40 return-to-duty process | Controlled by policy and applicable employment law |
Who is subject to FMCSA DOT testing?
Part 382 generally applies to drivers who operate commercial motor vehicles requiring a commercial driver’s license under Part 383. The test attaches to the safety-sensitive function, not to a job title or the size of the employer. Owner-operators are not outside the rule simply because they are self-employed. They have specific consortium and random-testing obligations.
An employer can have both DOT-covered and non-DOT employees. A CDL driver performing Part 382 safety-sensitive work belongs in the DOT program. A warehouse employee, office employee or driver of a vehicle that does not trigger the applicable DOT testing rule may fall under a separate non-DOT policy. A person can even be covered by different programs at different times, which makes accurate test designation essential.
What drugs are included in a DOT test?
Under 49 CFR 40.82, DOT laboratories test for five drugs or drug classes: marijuana metabolites, cocaine metabolites, amphetamines, opioids and phencyclidine, commonly called PCP. The regulation specifies the analytes, cutoffs, specimen procedures and laboratory requirements. A DOT specimen cannot be tested as a DOT test for extra drugs outside the authorized panel.
Non-DOT panels can differ. An employer might choose a panel tailored to its workforce, but it must do so under a written policy and after checking state restrictions. More substances do not automatically make a program better. The policy must define who is tested, why testing occurs, what specimen is used, how results are reviewed and what action follows.
DOT testing circumstances for commercial drivers
FMCSA’s Part 382 program includes distinct testing reasons. The reason placed on the federal form must match the event:
- Pre-employment: a negative controlled-substances test result is required before the driver first performs a safety-sensitive function, subject to the regulation’s limited exceptions.
- Random: selections must be made by a scientifically valid method, spread reasonably through the year and kept unpredictable.
- Post-accident: required only when the accident and citation criteria in 49 CFR 382.303 are met. Carrier policy should include a timely decision process and documentation when a required test is not completed.
- Reasonable suspicion: based on specific, contemporaneous observations made by a trained supervisor under the regulatory standard.
- Return-to-duty: required after the employee completes the Substance Abuse Professional process and before resuming DOT safety-sensitive work.
- Follow-up: a directly observed testing plan prescribed by the Substance Abuse Professional after return to duty.
A non-DOT policy may use similar labels, but the authority and procedure are not the same. For example, an employer’s post-incident test under company policy does not become a DOT post-accident test unless the Part 382 criteria are satisfied.
Specimens, collection and laboratories
Part 40 authorizes urine and oral-fluid drug testing methods, but a method is usable only when the required federal infrastructure is available and the collection is performed under current DOT rules. Point-of-collection instant tests and hair tests are not authorized as DOT drug tests. DOT laboratories in the United States must hold the required HHS certification for each methodology they perform.
The collection uses the federal custody and control process. The collector, laboratory, Medical Review Officer, employer representative and other service agents each have defined responsibilities. Non-DOT specimens should use a separate non-federal process. Mixing forms or instructing the laboratory to add a non-DOT panel to a DOT specimen creates avoidable compliance and confidentiality problems.
Marijuana remains prohibited in the federal program
State marijuana laws do not change the federal DOT rule. Part 40 does not permit a Medical Review Officer to verify a marijuana result as negative based on state-authorized medical marijuana or use of a hemp or other non-prescription marijuana-related product. Employers should explain this clearly to covered drivers without offering medical advice or guessing how a result will be verified.
What happens after a DOT violation?
A verified positive DOT drug test, a DOT alcohol violation or a refusal requires the employee to be removed from DOT safety-sensitive functions. The employee cannot return to those functions until completing the evaluation and education or treatment process directed by a qualified Substance Abuse Professional, receiving a return-to-duty determination and completing a negative return-to-duty test. Follow-up testing then continues according to the SAP’s plan.
The employer remains responsible for removing the employee from safety-sensitive work. A consortium or testing provider can administer program tasks, but it does not replace the employer’s regulatory responsibility.
Clearinghouse duties are specific to FMCSA-covered drivers
FMCSA employers must use the Drug and Alcohol Clearinghouse for required pre-employment and annual queries and must report information assigned to employers under Part 382. A driver with a prohibited status cannot perform a safety-sensitive function. Non-DOT workplace results are not converted into FMCSA Clearinghouse violations simply because the employee also holds a CDL.
Keep Clearinghouse, Part 40 and driver-qualification records organized according to the applicable retention and access rules. Do not place sensitive testing records in a general personnel file that is accessible to staff without a business need.
How to run both programs without mixing them
- Identify every safety-sensitive position and the DOT agency rule that applies.
- Maintain a DOT policy that follows Part 40 and Part 382, separate from any non-DOT workplace policy.
- Use test-order forms that clearly identify the program and test reason.
- Confirm that collectors, laboratories, MROs, SAPs and consortium administrators meet the qualifications required for their DOT roles.
- Train supervisors before they make reasonable-suspicion determinations.
- Keep selection lists and random pools accurate, especially after hires, terminations and changes in duty.
- Audit records for missing results, cancelled tests, late post-accident decisions and unresolved Clearinghouse statuses.
Official sources and related support
Use the current 49 CFR Part 40, 49 CFR Part 382 and DOT’s employee drug and alcohol testing guidance. For carrier-specific help, see DOT drug and alcohol consortium services and FMCSA Clearinghouse services.
Last reviewed August 18, 2026. General information only, not legal or employment advice.
Frequently asked questions
What is the main difference between DOT and non-DOT drug testing?
DOT testing follows 49 CFR Part 40 and the applicable DOT agency regulation. Non-DOT testing follows the employer's written policy and applicable state and local law.
What drugs are included in a DOT drug test?
Part 40 requires testing for marijuana metabolites, cocaine metabolites, amphetamines, opioids and phencyclidine, commonly called PCP.
Can a DOT drug test include extra drugs?
No. A specimen designated as a DOT specimen cannot be tested under the DOT program for drugs outside the panel authorized by Part 40. A separate non-DOT test may be used when lawful and supported by policy.
Can hair or an instant test be used for DOT testing?
No. Hair testing and point-of-collection instant drug tests are not authorized DOT test methods. Use only specimen methods and qualified service agents allowed by the current Part 40 process.
Does legal marijuana change a DOT test result?
No. State-authorized marijuana and hemp-product use do not provide an acceptable medical explanation for a positive marijuana result under Part 40.
What happens after a positive DOT test or refusal?
The employee must be removed from DOT safety-sensitive functions and cannot return until completing the required Substance Abuse Professional process and a negative return-to-duty test. Follow-up testing then applies.
Are non-DOT results reported to the FMCSA Clearinghouse?
A non-DOT workplace result does not become a Clearinghouse violation merely because the employee has a CDL. Clearinghouse reporting is tied to violations of FMCSA's Part 382 program.
Need practical help with this compliance task?
Compare DOT compliance providers with experience in the service your carrier needs, from registrations and driver files to testing programs, audits and ongoing safety management.